Form 4: Xencor CEO Exercises Options and Sells Shares Under 10b5-1 Plan

Xencor's CEO, Bassil I. Dahiyat, exercised stock options and sold shares on November 13, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On November 13, 2024, Xencor CEO Bassil I. Dahiyat exercised stock options to acquire 3,366 shares of common stock at a price of $15.69 per share.
• Simultaneously, Mr. Dahiyat sold 3,366 shares at a weighted average price of $24.0172 per share, with individual sales ranging from $24.00 to $24.07.
• These transactions were executed under a 10b5-1 trading plan adopted on June 14, 2024.
• The sale of shares was to cover the cost of the option exercise and estimated tax liabilities.
• Following these transactions, Mr. Dahiyat beneficially owns 352,615 shares of Xencor common stock.
• The report also corrects a clerical error from previous filings, adding 304 shares to the total previously reported.

Sentiment

Score: 6

Explanation: The document reflects routine transactions under a pre-arranged plan, with a minor correction of a clerical error. The sentiment is neutral to slightly positive due to the CEO exercising options, but the sale of shares tempers the positive sentiment.

Positives

• The CEO's transactions are part of a pre-planned 10b5-1 trading plan, which is a common practice to avoid insider trading concerns.
• The exercise of options indicates the CEO's belief in the company's long-term value.

Negatives

• The sale of shares, even if for tax purposes, could be interpreted negatively by some investors as a reduction in the CEO's stake.

Risks

• The market may react negatively to the CEO selling shares, even if it is part of a pre-planned strategy.
• Clerical errors in previous filings could raise concerns about the accuracy of other reported information.

Industry Context

The use of 10b5-1 trading plans is a common practice among corporate executives to manage their personal finances while avoiding accusations of insider trading. This filing is a routine disclosure of such activity.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard practice among executives at publicly traded companies, including those in the biotechnology sector like Xencor.
• Similar filings are regularly made by executives at companies such as Amgen, Regeneron, and Gilead, reflecting routine transactions under pre-arranged trading plans.
• The reported prices for the stock option exercise and sale are within the typical range for such transactions, given the company's stock performance.

Stakeholder Impact

• Shareholders may view the CEO's stock sale with mixed feelings, as it could be seen as a lack of confidence, despite being part of a pre-planned strategy.
• The correction of the clerical error may raise questions about the accuracy of past filings.

Key Dates

Keywords

Xencor, CEO, Bassil Dahiyat, stock options, share sale, 10b5-1 plan, insider trading, Form 4, equity securities